Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Etofamide is a luminal amoebicide used primarily for the treatment of intestinal amebiasis caused by *Entamoeba histolytica*. It belongs to the dichloroacetamide class of drugs. Its primary therapeutic value lies in its direct action against trophozoites within the intestinal lumen; because it is poorly absorbed from the gastrointestinal tract, it achieves high concentrations in the gut while maintaining a favorable safety profile with minimal systemic exposure. Clinical studies have demonstrated its efficacy in both adult and pediatric populations, typically administered in a multi-day regimen. While primarily used for amebiasis, it has also demonstrated some in vitro activity against other intestinal parasites like *Giardia lamblia*.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on etofamide.